Invest New Drugs. 2021 Feb;39(1):269-271. doi: 10.1007/s10637-020-00983-6. Epub 2020 Aug 11.

Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.

Investigational new drugs

Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, Norikazu Matsuo, Takaaki Tokito, Tomoaki Hoshino

PMID: 32783090 DOI: 10.1007/s10637-020-00983-6

Abstract

Although immune checkpoint inhibitors have improved the survival of small cell lung cancer (SCLC) patients, their efficacy in SCLC patients who relapsed after systemic chemotherapy is unclear. This retrospective study aimed to investigate the utility of treatment with atezolizumab plus carboplatin and etoposide in SCLC patients previously treated with platinum-based chemotherapy. We retrospectively screened consecutive eight SCLC patients who received atezolizumab plus carboplatin and etoposide after platinum-based chemotherapy. We evaluated the efficacy of this treatment and its association with programmed cell death-ligand 1 (PD-L1) expression. Three and five patients had sensitive relapse and refractory relapse for first-line platinum-based chemotherapy, respectively. The overall response rate and disease control rate was 37.5% and 75.0%, respectively. Median progression-free survival was 4.0 months. Out of three patients who achieved clinical response, two patients had refractory relapse for first-line platinum-based chemotherapy. No patient exhibited PD-L1 expression. Atezolizumab plus carboplatin and etoposide therapy was effective in SCLC patients with sensitive and refractory relapse and might be a second-line treatment option for SCLC patients previously treated with platinum-based chemotherapy.

Keywords: Chemotherapy; Immune checkpoint inhibitor; PD-L1; Small cell lung cancer

References

1. Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet 366:1385–1396. https://doi.org/10.1016/S0140-6736(05)67569-1 - PubMed
2. Rocha Lima CM, Chiappori A (2003) Treatment of relapsed small-cell lung Cancer--a focus on the evolving role of Topotecan. Lung Cancer 40:229–236. https://doi.org/10.1016/s0169-5002(03)00039-4 - PubMed
3. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. https://doi.org/10.1038/nrc3239 - PubMed
4. Horn L, Mansfield AS, Szczęsna A et al (2018) First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer. N Engl J Med 379:2220–2229. https://doi.org/10.1056/NEJMoa1809064 - PubMed
5. Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929–1939. https://doi.org/10.1016/S0140-6736(19)32222-6 - PubMed
6. von Pawel J, Jotte R, Spigel DR et al (2014) Randomized phase III trial of Amrubicin versus Topotecan as second-line treatment for patients with small-cell lung Cancer. J Clin Oncol 32:4012–4019. https://doi.org/10.1200/JCO.2013.54.5392 - PubMed
7. Goto K, Ohe Y, Shibata T et al (2016) Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 17:1147–1157. https://doi.org/10.1016/S1470-2045(16)30104-8 - PubMed
8. Brody R, Zhang Y, Ballas M et al (2017) PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 112:200–215. https://doi.org/10.1016/j.lungcan.2017.08.005 - PubMed
9. Chiang AC, Sequist LV, Gilbert J et al (2020) Clinical activity and safety of Atezolizumab in a phase 1 study of patients with relapsed/refractory small-cell lung Cancer. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2020.05.008 - PubMed

Publication Types

• Journal Article
• Research Support, Non-U.S. Gov't